Can-Fite (CANF) Surged 38% on Survival Data That Proves Nothing Yet — Measured

Can-Fite BioPharma reported that patients in its pivotal Phase III liver-cancer study of namodenoson are living longer than anticipated — and the stock repriced violently on data that, by the company's own statement, cannot yet show whether the drug works. Measured from the instant the headline crossed at 11:00 UTC on Tuesday 2 September 2026, Can-Fite moved +37.81% in the first minute and stood +30.49% fifteen minutes after the print, from $3.28, on volume our pipeline validated.

Key points

• Overall survival in the ongoing pivotal Phase III study is running longer than anticipated, per the company.
• The data is pooled and blinded — namodenoson and placebo arms together — so it supports no efficacy conclusion; Can-Fite is evaluating an earlier interim analysis in response.
• Measured reaction: +37.81% in minute one, +30.49% by minute fifteen, validated volume.

What the market actually bought

Read strictly, the announcement contains no evidence the drug outperforms placebo: longer pooled survival could mean the treatment arm is doing well, the control arm is doing well, or the enrolled population is simply hardier than the trial's assumptions. The company says exactly this. What changed today is timing and probability: survival long enough to surprise the trial's design pushes Can-Fite to evaluate an earlier interim analysis, which would unblind the namodenoson-versus-placebo comparison sooner than planned. For a stock priced near $3.28 before the print, the market treated a sooner, live shot at pivotal efficacy data as worth roughly a third more — with the first minute carrying most of the repricing and the window's fade from +37.81% to +30.49% showing some of the instant enthusiasm handed back as readers reached the blinded-data caveat.

The design behind the caveat

The study enrolls advanced hepatocellular carcinoma patients with underlying Child-Pugh B7 cirrhosis — a population with historically short survival — randomized 2:1 to namodenoson or placebo, with overall survival as the primary endpoint. A 2:1 design means two-thirds of the pooled population is on drug, which is why pooled longevity is suggestive to the market even while it proves nothing: the majority of the blended signal comes from treated patients. The interim analysis, under the study's statistical plan and regulatory requirements, is the mechanism that converts suggestion into an answer.

How these numbers were measured

Reaction figures are MoveSurge's own measurement: the price captured at the instant each headline crossed our tape, then one and fifteen minutes later, with volume validated against the window's norm. Case and trial details are attributed to the rulings and company announcements. The pipeline is described on our editorial standards page.